SCHEMBL21035341

SCHEMBL21035341

CC(C)(C)OC(=O)NC1CCN(C(=O)[C@@H]2C[C@@H](Oc3ccc(Cl)cc3)CCN2S(=O)(=O)c2ccc(OCC3CCCCC3)cc2)CC1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ACACB O00763 2/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
ADAM17 P78536 4/20 0.40
MMP1 P03956 4/20 0.40
MMP13 P45452 4/20 0.40
NPSR1 Q6W5P4 1/20 0.38
MMP9 P14780 1/20 0.38
LMNA P02545 2/20 0.37
ITGB1 P05556 1/20 0.37
ITGA4 P13612 1/20 0.37
GPR119 Q8TDV5 3/20 0.37
RGS12 O14924 1/20 0.37
SSTR4 P31391 1/20 0.36
GAA P10253 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21035127 0.98 ACACB (0.41) ACACBKMT2AMEN1ADAM17MMP1
SCHEMBL21035580 0.98 ACACB (0.41) ACACBKMT2AMEN1ADAM17MMP1
SCHEMBL21035662 0.98 ACACB (0.41) ACACBKMT2AMEN1ADAM17MMP1
SCHEMBL21034927 0.94 ACACB (0.42) ACACBKMT2AMEN1ADAM17MMP1
SCHEMBL21035086 0.94 ACACB (0.42) ACACBKMT2AMEN1ADAM17MMP1
SCHEMBL21035006 0.94 ACACB (0.42) ACACBKMT2AMEN1ADAM17MMP1
SCHEMBL21035644 0.94 ACACB (0.42) ACACBKMT2AMEN1ADAM17MMP1
SCHEMBL21036277 0.94 ACACB (0.42) ACACBKMT2AMEN1ADAM17MMP1
SCHEMBL21035536 0.92 ACACB (0.41) ACACBADAM17MMP1MMP13MMP9
SCHEMBL21035393 0.92 ACACB (0.41) ACACBADAM17MMP1MMP13MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019104011-A1 CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2019-05-31 WO disclosed